We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




HDL Subclasses Linked to Mortality in Heart Failure Patients

By LabMedica International staff writers
Posted on 11 Feb 2019
Heart failure (HF) is a frequent cause of morbidity and mortality worldwide and is defined by the as an abnormality of the cardiac structure and function, resulting in a diminished ability of the heart to maintain optimal perfusion of metabolizing tissues.

The link between high-density lipoproteins (HDL) subclasses and the prognosis of cardiovascular diseases remains controversial. More...
It is important to note that HDL particles comprise two major subclasses, namely large buoyant HDL2 particles and smaller, denser HDL3 particles. Accordingly, quantity of the total HDL-C is dominated by the contribution of the larger, cholesterol-rich HDL2.

Scientists at University of Zagreb School of Medicine (Zagreb, Croatia) and their colleagues evaluated the prognostic value of the HDL subclasses 3 and 2 cholesterol (HDL3-C, HDL2-C) as well as of total HDL-C for 3-month mortality in acute heart failure (AHF) patients. Serum samples of 132 patients [65 (49.2%) were female and median and range for age were 77.3 (45.5–92.4) years], were available for the analyses. Of these, 35 (26.5%) died within three months of onset of AHF.

The collection of the blood samples, the standard laboratory methods and measurements of small, large and total HDL-particles (HDL-P) have been described in previous reports on this AHF cohort. The levels of total HDL cholesterol (HDL-C) and HDL3-C were measured using detergent-based homogeneous assays from Denka Seiken Co., Ltd. on an Olympus AU680 automated analyzer. HDL2-C was estimated by subtracting HDL3-C from total HDL-C.

The team reported that the median and range for serum levels of HDL3-C, HDL2-C, and total HDL-C were 0.49 (0.23–0.85) mmol/L, 0.62 (0.19–1.67) mmol/L and 1.13 (0.42–2.46) mmol/L, respectively. Univariate logistic regression analyses revealed a significant inverse association of HDL3-C (odds ratio (OR) 0.46 per 1-SD increase, 95% confidence interval (CI) 0.27–0.72,) with 3-month mortality, whereas concentrations of total HDL-C and HDL2-C showed no significant association. After adjustment for various laboratory and clinical parameters known to be associated with mortality in heart failure patients, HDL3-C concentrations remained significantly associated with 3-month mortality (OR 0.34 per 1-SD increase, 95% CI 0.15–0.74).

The authors concluded that low admission serum levels of HDL3-C are associated with increased 3-month mortality in AHF patients, whereas total HDL-C and HDL2-C showed no association. HDL3-C might thus be useful as a prognostic parameter in AHF. The study was published in the March 2019 issue if the journal Clinica Chimica Acta.

Related Links:
University of Zagreb School of Medicine


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Automated Urinalysis Solution
UN-9000
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.